-
1.发明授权
公开(公告)号：EP2531180B1
公开(公告)日：2017-06-21
申请号：EP11737251.6
申请日：2011-01-18
发明人： WOO, Jong Soo , PARK, Jae Hyun , KIM, Yong Il , NA, Young Jun , KIM, Min Jung , LEE, Yun Ah
IPC分类号： A61K9/24 , A61K9/30 , A61K9/22 , A61K31/495 , A61K31/137
CPC分类号： A61K31/495 , A61K9/209 , A61K31/137 , A61K2300/00
-
2.发明公开COMPLEX FORMULATION COMPRISING ASPIRIN COATED WITH BARRIER CONTAINING HYDROPHOBIC ADDITIVE, AND HMG-COA REDUCTASE INHIBITOR 审中-公开与阿司匹林的复合制剂与疏水性添加剂锁是BESCHICHTETET和HMG-CoA还原酶
公开(公告)号：EP2531199A2
公开(公告)日：2012-12-12
申请号：EP11739961.8
申请日：2011-01-26
发明人： WOO, Jong Soo , PARK, Jae Hyun , KIM, Yong Il , NA, Young Jun , CHOI, Jun Young , LEE, Yun Ah
IPC分类号： A61K31/60 , A61K31/505 , A61K31/40 , A61P9/00
CPC分类号： A61K31/40 , A61K9/1652 , A61K9/5063 , A61K9/5084 , A61K31/505 , A61K31/616 , A61K45/06 , A61K2300/00
摘要： Provided is a complex formulation for the prevention or treatment of cardiovascular diseases, comprising: a) aspirin coated with a barrier containing a hydrophobic additive; and b) an HMG-CoA reductase inhibitor, which has improved storage stability by preventing the deterioration in the stability of HMG-CoA reductase which is caused by salicylic acid, thereby being used in the treatment of hypertension and hypercholesterolemia.
-
公开(公告)号：EP2531180A2
公开(公告)日：2012-12-12
申请号：EP11737251.6
申请日：2011-01-18
发明人： WOO, Jong Soo , PARK, Jae Hyun , KIM, Yong Il , NA, Young Jun , KIM, Min Jung , LEE, Yun Ah
IPC分类号： A61K9/24 , A61K9/30 , A61K9/22 , A61K31/495
CPC分类号： A61K31/495 , A61K9/209 , A61K31/137 , A61K2300/00
摘要： An oral complex composition which comprises (i) a core comprising a swellable hydrogel-forming agent and pseudoephedrine, or a pharmaceutically acceptable salt thereof; (ii) a first coating layer encasing the core which comprises a water-soluble substance; and (iii) a second coating layer deposited on the first coating layer which comprises levocetirizine or a pharmaceutically acceptable salt thereof together with polyvinylalcohol, povidone, polyvinylalcohol-polyethyleneglycol graft copolymer or a mixture thereof, has an improved levocetirizine releasing rate and does not show a delayed release behavior even after a long storage period. Accordingly, the inventive oral complex composition is useful for treating perennial or seasonal allergic diseases including nasal obstruction, sneezing, and rhinorrhea.
-
-
搜索结果
3 条记录 (耗时 0.009 秒)
